Lead Product(s): Landiolol Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Onoact
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
This approval is based on the result of a multi-center, randomized, open-label, parallel-group, late Phase Ⅱ / Ⅲ study (J-Land 3S study: ONO-1101-32) conducted in Japan, in patients with tachyarrhythmia associated with sepsis.
Lead Product(s): Evolocumab
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 23, 2020
Under the acquisition, Amgen Astellas BioPharma will change its name to Amgen K.K., and simultaneously relocate its Headquarters to Tokyo Midtown.